Literature DB >> 28498263

Cochlear Implantation in Patients With Usher Syndrome Type IIa Increases Performance and Quality of Life.

Bas P Hartel1, Josephine W I van Nierop, Wendy J Huinck, Liselotte J C Rotteveel, Emmanuel A M Mylanus, Ad F Snik, Henricus P M Kunst, Ronald J E Pennings.   

Abstract

OBJECTIVES: Usher syndrome type IIa (USH2a) is characterized by congenital moderate to severe hearing impairment and retinitis pigmentosa. Hearing rehabilitation starts in early childhood with the application of hearing aids. In some patients with USH2a, severe progression of hearing impairment leads to insufficient speech intelligibility with hearing aids and issues with adequate communication and safety. Cochlear implantation (CI) is the next step in rehabilitation of such patients. This study evaluates the performance and benefit of CI in patients with USH2a.
DESIGN: Retrospective case-control study to evaluate the performance and benefit of CI in 16 postlingually deaf adults (eight patients with USH2a and eight matched controls). Performance and benefit were evaluated by a speech intelligibility test and three quality-of-life questionnaires.
RESULTS: Patients with USH2a with a mean age of 59 years at implantation exhibited good performance after CI. The phoneme scores improved significantly from 41 to 87% in patients with USH2a (p = 0.02) and from 30 to 86% in the control group (p = 0.001). The results of the questionnaire survey demonstrated a clear benefit from CI. There were no differences in performance or benefit between patients with USH2a and control patients before and after CI.
CONCLUSIONS: CI increases speech intelligibility and improves quality of life in patients with USH2a.

Entities:  

Mesh:

Year:  2017        PMID: 28498263     DOI: 10.1097/MAO.0000000000001441

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  7 in total

1.  The First Epiretinal Implant for Hereditary Blindness in the Asia-Pacific Region.

Authors:  Ryan T Yanagihara; Maya L M Yamane; Gregg T Kokame
Journal:  Hawaii J Health Soc Welf       Date:  2021-11

2.  Outcomes of cochlear implantation in children with Usher syndrome: a long-term observation.

Authors:  Agnieszka Remjasz-Jurek; Pedro Clarós; Astrid Clarós-Pujol; Carmen Pujol; Andrés Clarós
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-10-15       Impact factor: 3.236

Review 3.  Review of Genotype-Phenotype Correlations in Usher Syndrome.

Authors:  Eric Nisenbaum; Torin P Thielhelm; Aida Nourbakhsh; Denise Yan; Susan H Blanton; Yilai Shu; Karl R Koehler; Aziz El-Amraoui; Zhengyi Chen; Byron L Lam; Xuezhong Liu
Journal:  Ear Hear       Date:  2022 Jan/Feb       Impact factor: 3.562

4.  Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations.

Authors:  Kalyan Dulla; Ralph Slijkerman; Hester C van Diepen; Silvia Albert; Margo Dona; Wouter Beumer; Janne J Turunen; Hee Lam Chan; Iris A Schulkens; Lars Vorthoren; Cathaline den Besten; Levi Buil; Iris Schmidt; Jiayi Miao; Hanka Venselaar; Jingjing Zang; Stephan C F Neuhauss; Theo Peters; Sanne Broekman; Ronald Pennings; Hannie Kremer; Gerard Platenburg; Peter Adamson; Erik de Vrieze; Erwin van Wijk
Journal:  Mol Ther       Date:  2021-04-23       Impact factor: 12.910

5.  A novel homozygous variant of GPR98 causes usher syndrome type IIC in a consanguineous Chinese family by next generation sequencing.

Authors:  Chunli Wei; Lisha Yang; Jingliang Cheng; Saber Imani; Shangyi Fu; Hongbin Lv; Yumei Li; Rui Chen; Elaine Lai-Han Leung; Junjiang Fu
Journal:  BMC Med Genet       Date:  2018-06-11       Impact factor: 2.103

6.  Severe or Profound Sensorineural Hearing Loss Caused by Novel USH2A Variants in Korea: Potential Genotype-Phenotype Correlation.

Authors:  Sang-Yeon Lee; Kwangsic Joo; Jayoung Oh; Jin Hee Han; Hye-Rim Park; Seungmin Lee; Doo-Yi Oh; Se Joon Woo; Byung Yoon Choi
Journal:  Clin Exp Otorhinolaryngol       Date:  2019-11-02       Impact factor: 3.372

Review 7.  Usher syndrome: clinical features, molecular genetics and advancing therapeutics.

Authors:  Maria Toms; Waheeda Pagarkar; Mariya Moosajee
Journal:  Ther Adv Ophthalmol       Date:  2020-09-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.